Clinical Trials Logo

MGMT-Unmethylated Glioblastoma clinical trials

View clinical trials related to MGMT-Unmethylated Glioblastoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05879250 Not yet recruiting - Clinical trials for Glioblastoma, IDH-Wildtype

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Start date: December 27, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.

NCT ID: NCT05694416 Not yet recruiting - Clinical trials for MGMT-Unmethylated Glioblastoma

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.